New drug aims to outsmart recurrent lymphoma

NCT ID NCT07187960

Not yet recruiting Disease control Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tests a new drug called TQB2825, a bispecific antibody that targets both CD3 and CD20 proteins, against standard immunotherapy for people with follicular lymphoma that has returned or not responded to treatment. About 228 participants will be randomly assigned to receive either TQB2825 or a combination of rituximab and chemotherapy. The main goal is to see if TQB2825 can delay cancer progression better than the current approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB2825 injection (a bispecific antibody targeting CD3 and CD20)
What this could lead to: If it works, this could offer a new treatment option for people with follicular lymphoma that has come back or not responded to prior therapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not be more effective than existing treatments and could have side effects like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA

Contacts and locations

Locations

Affiliated Cancer Hospital of Harbin Medical University

Harbin, Heilongjiang, 150081, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Gansu Provincial Hospital

Lanzhou, Gansu, 730030, China
General Hospital of Ningxia Medical University

Yinchuan, Ningxia, 750000, China
Hainan General Hospital

Haikou, Hainan, 570311, China
Henan Cancer Hospital

Zhengzhou, Henan, 450000, China
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, 301636, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China
Jiangxi Cancer Hospital

Nanchang, Jiangxi, 330029, China
Linyi City People Hospital

Linyi, Shandong, 276000, China
People's Hospital of Hunan Province

Changsha, Hunan, 410005, China
People's Hospital of Tianjin

Tianjin, Tianjin Municipality, 300121, China
People's Hospital of Xinjiang Uygur Autonomous Region

Ürümqi, Xinjiang, 830000, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200023, China
Shanxi Provincial Cancer Hospital

Taiyuan, Shanxi, 030000, China
Shengjing Hospital Of China Medical University

Shenyang, Liaoning, 110134, China
Sun Yet-Sen University Cancer Certer

Guangzhou, Guangdong, 510700, China
The Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, 550004, China
The First Affiliated Hospital Of Zhengzhou University

Zhengzhou, Henan, 450000, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400010, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, 710061, China
The First People's Hospital Of Yunnan Province

Kunming, Yunnan, 650100, China
The Second Hospital Of Dalian Medical University

Dalian, Liaoning, 116000, China
Tianjin Cancer Hospital Airport Hospital

Tianjin, Tianjin Municipality, 300308, China
Tongji Hospital of Tongji University

Shanghai, Shanghai Municipality, 200065, China
Yantai Yuhuangding Hospital

Yantai, Shandong, 264000, China
Yunan Cancer Hospital

Kunming, Yunnan, 650118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.